ImpediMed Limited (IPD.AX)
| Previous close | 0.0830 |
| Open | 0.0840 |
| Bid | 0.0830 x 53590500 |
| Ask | 0.0840 x 50748300 |
| Day's range | 0.0830 - 0.0860 |
| 52-week range | 0.0800 - 0.2050 |
| Volume | |
| Avg. volume | 1,399,903 |
| Market cap | 161.937M |
| Beta (5Y monthly) | 3.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
New Bone Data Showing Strong Correlation between ImpediMed's SOZO and DXA in Cancer Patients Presented at 39th Annual Miami Breast Cancer Conference
ImpediMed Limited (ASX.IPD), a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximize patient health is pleased to announce a poster showing strong correlation between ImpediMed's SOZO® Digital Health Platform and dual x-ray absorptiometry (DXA) for assessing bone mineral content in cancer patients was presented at the 39th Annual Miami Breast Cancer Conference on 3-6 March 2022 in Miami Beach, Florida, USA.
- PR Newswire
New Data Evaluating ImpediMed's SOZO® Digital Health Platform to Assess Bone in Cancer Patients to be Presented at 39th Annual Miami Breast Cancer Conference
ImpediMed Limited (ASX.IPD), a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximize patient health is pleased to announce an abstract comparing concurrent measures using ImpediMed's SOZO® Digital Health Platform and dual x-ray absorptiometry (DXA) for assessing bone mineral content in cancer patients was accepted for poster presentation at the 39th Annual Miami Breast Cancer Conference on 3-6 March 2022 in Miami Beach, Florida, USA
- PR Newswire
New Data Show Statistically Significant Reduction in Chronic Cancer-Related Lymphedema with Early Detection Using ImpediMed's L-Dex® Technology and Intervention
ImpediMed Limited (ASX: IPD), a global medical technology company using bioimpedance spectroscopy (BIS) to generate powerful data to maximize patient health, today announced publication of results from the PREVENT trial showing that fewer breast cancer patients with early detection using L-Dex and intervention progressed to chronic lymphedema when compared to patients monitored with tape measure, which is the current standard of care. The result was statistically significant.
